Stay updated on Johnson & Johnson Press Releases
Sign up to get notified when there's something new on the Johnson & Johnson Press Releases page.

Latest updates to the Johnson & Johnson Press Releases page
- CheckyesterdayChange DetectedThe page now highlights that TREMFYA® is the only IL-23 inhibitor proven to significantly inhibit joint structural damage in active psoriatic arthritis, and it includes new leadership information with the election of Daniel Pinto to the Board of Directors. Additionally, the ETHICON™ 4000 Stapler has been launched, showcasing advanced surgical technology.SummaryDifference100%
- Check8 days agoChange DetectedThe webpage has been updated with significant new clinical data regarding multiple myeloma treatments, including promising results for DARZALEX FASPRO® and CARVYKTI®, as well as the launch of the KINCISE™ 2 System for surgical procedures. Additionally, the page reflects a new date of June 3, 2025, indicating a focus on upcoming events and data releases.SummaryDifference100%
- Check15 days agoChange DetectedThe webpage has been updated to include new data on cancer treatments, particularly highlighting advancements in CARVYKTI® and AKEEGA® for multiple myeloma and prostate cancer, as well as the launch of SOUNDSTAR CRYSTAL™ for cardiac imaging. Additionally, the page reflects a change in the number of results from 2,134 to 2,137.SummaryDifference100%
- Check22 days agoChange DetectedThe page has been updated to include new findings from the Shockwave Medical study presented at EuroPCR 2025, highlighting the benefits of an IVL-first strategy for female patients with complex calcified lesions. Additionally, the page reflects a change in the number of results from 2,130 to 2,133.SummaryDifference100%
- Check30 days agoChange DetectedThe webpage has added significant new content regarding advancements in breast cancer reconstruction and psoriasis treatment, while also removing older clinical trial data and conference participation announcements.SummaryDifference100%
- Check37 days agoChange DetectedThe webpage has been updated with significant new data regarding the FDA approvals and clinical trial results for several treatments, including TREMFYA® and IMAAVYTM, which are crucial for patients with ulcerative colitis and generalized myasthenia gravis. Additionally, there are new insights into the oncology care landscape and the performance of TAR-200 in bladder cancer treatment.SummaryDifference100%
Stay in the know with updates to Johnson & Johnson Press Releases
Enter your email address, and we'll notify you when there's something new on the Johnson & Johnson Press Releases page.